Scenic Biotech

Scenic’s core platform is Cell-Seq, a functional genomics system used to identify genetic modifier targets. The company’s therapeutic concept is “modifier therapy,” in which treatment aims to shift disease severity by acting on modifier genes rather than the primary mutation.

Scenic’s primary focus is severe neuro-metabolic and metabolic diseases, including lysosomal disorders and related neurodegenerative conditions. The company has also disclosed earlier-stage oncology-related work based on modifier targets.

Scenic’s most advanced disclosed internal program is a brain-penetrant small-molecule inhibitor targeting PLA2G15, with IND-enabling studies ongoing and intended applications in rare disorders including Batten disease, Niemann-Pick type C, and frontotemporal lobar degeneration. Additional disclosed programs include a Galactokinase inhibitor for galactosemia and an ABHD18 mitochondrial modifier program being developed with an antisense oligonucleotide approach, alongside multiple undisclosed neurometabolic targets in validation.

In January 2026, Scenic announced a license and research agreement with Ono Pharmaceutical to use Cell-Seq for discovery of novel therapeutic targets. In September 2025, Scenic appointed Roland W. Bürli as Chief Scientific Officer. In 2025, the company also highlighted peer-reviewed publications supporting modifier-target discovery, including work linked to PLA2G15 and ABHD18.

Scenic has not reported human efficacy data for its internal rare-disease pipeline. Disclosures to date have focused on target discovery validation, preclinical datasets, and IND-enabling progress for the lead program.

Near-term milestones are centered on completion of IND-enabling work for the PLA2G15 inhibitor program and progression of additional internal targets from validation into development candidate selection. Timing for first-in-human studies will depend on completion of preclinical packages and regulatory submissions.

Scenic is led by an executive team spanning biotech company building, drug discovery, and translational development, with board-level experience in rare disease company leadership and financing. The company has continued to augment leadership to support transition from discovery into development-stage execution.